- Delivery Method:
- VIA Electronic Mail
- Reference #:
Recipient NameStewart I. Edington
- Dougherty's Pharmacy
5924 Royal Lane
Dallas, TX 75230
- Issuing Office:
- Office of Pharmaceutical Quality Operations Division II
The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (WL # 2017-DAL-WL-22), dated May 12, 2017. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.
You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
If you have any question, please do not hesitate to contact me at John.Diehl@fda.hhs.gov.
CDR John W. Diehl, M.S.
Director, Compliance Branch
Office of Pharmaceutical Quality Operations,